Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rx

Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group.

When applied to the scalp, Applied Biology’s novel TAAR receptor agonist reduces the force exerted by the ponytail on hair follicles; thus, reducing the likelihood of traction alopecia.

"China is the world's second largest hair market. We are excited to team with the Hairmore Group, China's premier hair surgery and treatment centers, to provide this groundbreaking therapy to women," says Andy Goren, MD, Chief Medical Officer of Applied Biology, in a news release.